In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Over the past week, 147 more cases were reported in an unexplained outbreak in a remote region of the Democratic Republic of ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

Africa saw a notable jump in mpox cases last week, with a continuing rise in novel clade 1b detections and shifts in ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...